WithdrawnNot Applicable

Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma

Stopped: No accrual

0Started 2004-12

Plain-language summary

RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) using fludeoxyglucose F 18, may help in learning how well chemotherapy works to kill cancer cells and allow doctors to plan better treatment. Comparing results of diagnostic procedures done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying positron emission tomography using fludeoxyglucose F 18 to see how well it works in predicting response to treatment in patients who are receiving rituximab and combination chemotherapy for newly diagnosed non-Hodgkin's lymphoma.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Histologically confirmed newly diagnosed non-Hodgkin's lymphoma (NHL) * Intermediate- or high-grade disease * Stage I-IV disease * Any of the following subtypes are allowed: * Diffuse large B-cell lymphoma * Anaplastic large cell lymphoma * Mantle cell lymphoma * Grade 3 follicular lymphoma * Mediastinal B-cell lymphoma * The following subtypes are not allowed: * Lymphoblastic lymphoma * Mycosis fungoides/Sézary's syndrome * HTLV-1 associated T-cell leukemia or lymphoma * Primary CNS lymphoma * HIV-associated lymphoma * Transformed lymphoma * Burkitt's lymphoma * Adequate staging of lymphoma by any of the following methods: * CT scan or MRI of affected sites * Unilateral or bilateral bone marrow biopsy * Positive pre-treatment positron emission tomography (PET) scan * Lumbar puncture * Radiographically measurable disease by PET scan * Any International Prognostic Index risk category allowed * No prior diagnosis of another hematologic malignancy NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology. PATIENT CHARACTERISTICS: Age * 18 and over Performance status * Not specified Life expectancy * Not specified Hematopoietic * Absolute neutrophil cou…

What they're measuring

Complete remission as measured by positron emission tomography (PET) at 7-10 days after R-CHOP, and after completion of study treatment

Timeframe: at 7-10 days after R-CHOP, and after completion of study treatment

Overall survival at 7-10 days after R-CHOP, and after completion of study treatment

Timeframe: at 7-10 days after R-CHOP, and after completion of study treatment

Disease-free survival at 7-10 days after R-CHOP, and after completion of study treatment

Timeframe: at 7-10 days after R-CHOP, and after completion of study treatment

Trial details

NCT IDNCT00110006

SponsorCase Comprehensive Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Lymphoma trials

Plain-language summary

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Complete remission as measured by positron emission tomography (PET) at 7-10 days after R-CHOP, and after completion of study treatment

Timeframe: at 7-10 days after R-CHOP, and after completion of study treatment

Overall survival at 7-10 days after R-CHOP, and after completion of study treatment

Timeframe: at 7-10 days after R-CHOP, and after completion of study treatment

Disease-free survival at 7-10 days after R-CHOP, and after completion of study treatment

Timeframe: at 7-10 days after R-CHOP, and after completion of study treatment